FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus …
Sep 18, 2024 · Merck provided KEYTRUDA and support for the trial, which investigated the efficacy and safety of KEYTRUDA in combination with pemetrexed and platinum chemotherapy.
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus …
Nov 16, 2023 · Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone. Approval marks seventh gastrointestinal cancer indication for KEYTRUDA-based regimens and 38th indication for KEYTRUDA in the US.
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA …
RAHWAY, N.J., March 21, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYLYNK-006 trial evaluating KEYTRUDA, Merck’s...
FDA approves pembrolizumab with chemotherapy for primary …
On June 17, 2024, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with...
FDA approves pembrolizumab combination for the first-line …
On October 13,2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) in combination with chemotherapy, with or without bevacizumab, for patients with persistent,...
Merck wins first FDA approval for Keytruda as a treatment for ...
Sep 18, 2024 · Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer...
Merck raises 2024 profit forecast on surging sales of cancer drug Keytruda
Apr 25, 2024 · Merck & Co on Thursday raised its annual profit and revenue forecasts on the back of double-digit growth for its blockbuster cancer drug Keytruda, the world's top selling prescription medicine.
Merck tops earnings estimates on strong demand for Keytruda, …
Oct 31, 2024 · Here's what Merck reported for the third quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: Earnings per share: $1.57 adjusted vs. $1.50 expected. Revenue ...
BioNTech pays $800M to take control of potential Keytruda killer
21 hours ago · Now, the biotech has struck a deal to gain full control of PM8002, a bispecific also known as BNT327. BioNTech is paying $800 million and committing up to $150 million in milestones to buy ...
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus …
Jun 17, 2024 · KEYTRUDA is now the first and only anti-PD-1 therapy FDA-approved in combination with chemotherapy for adult patients with primary advanced or recurrent endometrial carcinoma regardless of mismatch repair status. Approval marks the third FDA-approved indication for KEYTRUDA in endometrial carcinoma and …
- Some results have been removed